Phase I Study of Fostamatinib, a SYK inhibitor, in patients with Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia who have failed therapy with Hypomethylating Agents
MD Anderson Study Status
This phase I trial is to find out the best dose, possible benefits and/or side effects of fostamatinib in treating patients with lower-risk myelodysplastic syndromes or chronic myelomonocytic leukemia who have failed therapy with hypomethylating agents. Fostamatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome
Guillermo Montalban Bravo
For general questions about clinical trials:
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.